Weyerhaeuser Co. (WY) failed to extend gains with the stock declining -0.42% or $-0.14 to close the day at $33.52 on light trading volume of 3.4M shares, compared to its three month average trading volume of 4.27M. The Federal Way Washington 98003 based company has been outperforming the lumber, wood production group over the past 52 weeks, with the stock gaining 46.5%, compared to the industry which has advanced 48.92% over the same period. With RSI of 65.29, the stock should still continue to rise and get closer to its one year target estimate of $34.46, making it a hold for now.
Weyerhaeuser Co. is a real estate investment trust. It primarily invests in United States. The firm operates under four business segments, timberlands, wood products, cellulose fibers and real estate. It owns timberlands primarily in the U.S and has long-term licenses in Canada. The firm manufactures wood and specialty cellulose fibers products, and develops real estate, primarily as a builder of single-family homes. Weyerhaeuser Co was founded in 1900 and is based in Seattle, Washington.
Celgene Corporation (CELG) fell -1.5% during last trading as the stock lost $-1.81 to finish the day at $118.66 with about 3.38M shares changing hands, compared to its three month average trading volume of 4.27M. The $92.88B market cap company, which fluctuated between $118.25 and $120.77 during the day, currently situated 25.71% above its 52 week low of $94.39 and -6.57% away from its one year high of $127. The RSI of 57.2 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; and Jounce Therapeutics, Inc.; The company was founded in 1980 and is headquartered in Summit, New Jersey.
Campbell Soup Company (CPB) saw its value decrease by -1.42% as the stock dropped $-0.9 to finish the day at a closing price of $62.55. The stock was higher in trading and has fluctuated between $52.59-$67.89 per share for the past year. The shares, which traded within a range of $61.86 to $63.87 during the day, are up by 14.51% in the past three months and up by 4.79% over the past six months. It is currently trading -0.68% below its 20 day moving average and 2.4% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $60 a share over the next twelve months. The current relative strength index (RSI) reading is 51.52. The technical indicator lead us to believe there will be no major movement any time soon, hold.
Campbell Soup Company, together with its subsidiaries, manufactures and markets food and beverage products. It operates through three segments: Americas Simple Meals and Beverages; Global Biscuits and Snacks; and Campbell Fresh. The Americas Simple Meals and Beverages segment engages in the retail and food service of Campbell’s condensed and ready-to-serve soups; Swanson broth and stocks; Prego pasta sauces; Pace Mexican sauces; Campbell’s gravies, pastas, beans, and dinner sauces; Swanson canned poultry; Plum food and snacks; V8 juices and beverages; and Campbell’s tomato juices. The Global Biscuits and Snacks segment provides Pepperidge Farm cookies, crackers, bakery, and frozen products in the United States retail; and Arnott’s biscuits in Australia and the Asia Pacific; and Kelsen cookies worldwide, as well as meals and shelf-stable beverages in Australia and the Asia Pacific. The Campbell Fresh segment provides Bolthouse Farms fresh carrots, carrot ingredients, refrigerated beverages, and refrigerated salad dressings; and Garden Fresh Gourmet salsa, hummus, dips, and tortilla chips, as well as refrigerated soups. The company sells its products through retail food chains, mass discounters, mass merchandisers, club stores, convenience stores, drug stores, and dollar stores, as well as other retail, commercial, and non-commercial establishments; and independent contractor distributors. Campbell Soup Company was founded in 1869 and is headquartered in Camden, New Jersey.